Sionna Pharma (SION): Rasio utang marang kapitalisasi buku

Sionna Corp (SION) - logo korporat

The price chart for Sionna Therapeutics Inc (SION) on GURU.Markets demonstrates an asset shielded from macroeconomic shocks by stable demand for medtech, where the indicator stands at 0.03. The business specializes in cystic fibrosis treatment, facing regulatory hurdles and patent competition. To optimize costs, Sionna Therapeutics Inc (SION) outsources drug production and testing to external contractors, focusing exclusively on science.

Sionna Therapeutics Inc - Utang-utang marang aset resik SION (periode 08.02.2025 - 29.10.2026)
Produk asli Sionna Pharma

This indicator assesses credit risks through the ratio of total borrowed funds to the book value of equity, where a lower coefficient minimizes the probability of losses during market shocks. By analyzing the dynamic trend of financial leverage on the balance sheet, an investor can observe the balance between debt load and profitability, which is critical for Sionna Therapeutics Inc (SION) when financing costly RNA research and joint developments of cystic fibrosis drugs.

Pesaing Sionna Therapeutics Inc

Utang-utang marang kapitalisasi buku TEM (Tempus AI Inc)|Utang-utang marang kapitalisasi buku qiagen.com QGEN|IONS - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Repligen Corp RGEN|RNA: Utang-utang marang kapitalisasi buku|CRSP - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku GeneDx Holdings Corp.|Utang-utang marang nilai buku ultragenyx.com RARE|Rasio utang marang kapitalisasi buku Beam Therapeutics (BEAM)|Sarepta Therapeutics - Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku Twist Bio TWST|TXG: Rasio utang marang nilai buku|Intellia Therapeutics - Utang-utang marang kapitalisasi buku|STOK - Utang-utang marang kapitalisasi buku|BLFS (BioLife Solutions) - Utang marang nilai buku|Wave Life Sciences Ltd - Rasio utang marang aset resik|Utang marang nilai buku MAZE|PRME (Prime Medicine Bio) - Utang marang modal buku|Utang-utang marang kapitalisasi buku TSHA|QURE (uniqure.com) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku MGTX (MeiraGTx)|REGENXBIO Inc (RGNX) - Utang-utang marang nilai buku|SLDB - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik OCGN (Ocugen Pharma)|PACB: Utang-utang marang kapitalisasi buku|benitec.com (BNTC) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Design Therapeutics, Inc.|Rocket Pharma - Rasio utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku FDMT|LXEO - Utang-utang marang nilai buku|Korro Bio - Utang marang nilai buku|Utang-utang marang kapitalisasi buku editasmedicine.com EDIT|SLN: Utang marang nilai buku|ProQR Therapeutics N.V. - Utang marang modal buku|CDXS: Utang-utang marang kapitalisasi buku|SGMO - Utang-utang marang aset resik|NAUT (Nautilus Biotechnology, Inc.) - Utang-utang marang kapitalisasi buku|Utang marang nilai buku metagenomi.co (MGX)|Rasio utang marang kapitalisasi buku Precision BioSciences, Inc. (DTIL)|Utang-utang marang aset resik generationbio.com|Boundless Bio, Inc - Utang marang nilai buku|Rasio utang marang aset resik XCUR|Celsion Corporation - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku RNAZ|BNGO (Bionano Genomics Inc.) - Utang-utang marang kapitalisasi buku|Utang marang nilai buku Applied DNA Corp (APDN)|Rasio utang marang kapitalisasi buku bluebird bio, Inc. (BLUE)|Utang-utang marang aset resik immunoprecise.com|Utang-utang marang kapitalisasi buku OMGA (Omega Therapeutics, Inc.)|Utang-utang marang aset resik Singular Genomics Systems, Inc. (OMIC)|RGLS - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Syros Pharmaceuticals, Inc|Telesis Bio, Inc. (TBIO) - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku TCON|UBX (Unity Biotechnology, Inc.) - Utang-utang marang kapitalisasi buku